ArticleNeurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics2026
CCR5 protects against permanent brain ischemia by suppressing neuronal ferroptosis through AMPK/ACC signaling.
Article in Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ischemic stroke triggers devastating neuronal injury cascades, and ferroptosis acts as a key mediator of post-ischemic neuronal loss. Although C-C chemokine receptor type 5 (CCR5) has been traditionally implicated in post-stroke neuroinflammation, its cell-specific role in neuronal ferroptosis remains obscure. Here, we combined single-cell transcriptomic analysis, a permanent middle cerebral artery occlusion (pMCAO) mouse model, and in vitro hypoxia-ischemia-mimicking conditions to define an endogenous neuroprotective role for neuronal CCR5. Single-cell RNA sequencing revealed a marked upregulation of the CCL-CCR signaling pathway, with CCR5 identified as a prominent hub mediating intercellular interactions. In vivo, CCR5 was significantly elevated in peri-infarct neurons from 48 h up to one month after pMCAO, rather than microglia or astrocytes, suggesting an intrinsic stress response. In vitro, hypoxia-ischemia-mimicking conditions in SH-SY5Y cells and primary cortical neurons recapitulated this compensatory yet insufficient CCR5 induction alongside HIF-1α upregulation, GPX4 depletion, and severe lipid peroxidation. Functional studies demonstrated that CCR5 knockdown or pharmacological inhibition with maraviroc (MVC) further aggravated GPX4 reduction and lipid peroxide accumulation, whereas CCR5 overexpression substantially restored anti-ferroptotic capacity. CCR5 positively regulated AMPK and ACC phosphorylation, and inhibition of AMPK completely abolished CCR5-mediated GPX4 preservation and anti-ferroptotic defense. In vivo, MVC administration further accelerated peri-infarct iron deposition, reduced neuronal survival, and significantly worsened long-term motor deficits in pMCAO mice. Collectively, these findings identify a previously unrecognized endogenous adaptive mechanism whereby ischemia-induced neuronal CCR5 limits ferroptosis through AMPK/ACC-mediated GPX4 maintenance, providing a novel therapeutic conceptualization for strengthening endogenous protective cues in ischemic stroke.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.